Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
|Articles|November 30, 2022
FDA Approves First-Ever Fecal Microbiota, RBX2660, for C Difficile Recurrence
Author(s)Nina Cosdon
Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.
Advertisement
This evening, the US Food and Drug Administration (FDA) approved its first fecal microbiota product,
RBX2660 was approved to prevent recurrent
“Recurrent CDI impacts an individual’s quality of life and can also potentially be life-threatening,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research. “As the first FDA-approved fecal microbiota product, today’s action represents an important milestone, as it provides an additional approved option to prevent recurrent CDI.”
The therapy was developed by Ferring Pharmaceuticals, and is produced in a standardized manner, “With donor screening standardized, composition of numbers of bacteria standardized, and patient follow-up standardized,” said Sahil Khanna, MBBS, MS, a professor at the Mayo Clinic.
C difficile causes severe disease by inflating the colon and causing potentially life-threatening diarrhea. The
Recurrent C diff infection is associated with even higher rates of morbidity and mortality, treatment options are limited or may worsen the problem by further disrupting the gut microbiome. RBX2660 is an alternative to both taking more antibiotics and
RBX2660 is administered rectally in 1 dose. The safety and efficacy of the treatment were assessed in 2 randomized, double-blind, placebo-controlled clinical studies and from numerous other open-label studies.
Statistical analyses of treatment efficacy suggest recurrent CDI was prevented in 70.6% of RBX2660 recipients, as compared to 57.5% reduction of placebo recipients. The majority of adverse events were mild, and the most commonly reported side effects were abdominal pain, bloating, diarrhea, gas, and nausea.
Advertisement
Related to this article
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: September 25, 2026
2
US Company Recalls Thousands of Pounds of Uninspected Meat
3
Enivronmental Stewardship: The Role of Antimicrobials in Climate Change
4
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
5